Eliem Therapeutics - ELYM Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $6.00
  • Forecasted Upside: 118.98%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.74
▲ +0.12 (4.58%)

This chart shows the closing price for ELYM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Eliem Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ELYM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELYM

Analyst Price Target is $6.00
▲ +118.98% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Eliem Therapeutics in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 118.98% upside from the last price of $2.74.

This chart shows the closing price for ELYM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 investment analysts is to hold stock in Eliem Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/29/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/8/2023HC WainwrightReiterated RatingNeutral$6.00Low
2/10/2023HC WainwrightDowngradeBuy ➝ NeutralLow
10/28/2022HC WainwrightInitiated CoverageBuy$6.00Low
8/16/2022SVB LeerinkLower TargetOutperform$9.00 ➝ $4.00Low
8/2/2022Stifel NicolausLower Target$35.00 ➝ $8.00Low
7/11/2022SVB LeerinkLower TargetOutperform$13.00 ➝ $9.00N/A
4/26/2022SVB LeerinkLower TargetOutperform$33.00 ➝ $13.00High
4/25/2022GuggenheimDowngradeBuy ➝ NeutralHigh
9/8/2021Evercore ISIInitiated CoverageOutperformHigh
9/7/2021SVB LeerinkInitiated CoverageOutperform$33.00High
9/7/2021GuggenheimInitiated CoverageBuy$32.00High
9/7/2021Stifel NicolausInitiated CoverageBuy$35.00High
(Data available from 2/22/2019 forward)

News Sentiment Rating

1.03 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/25/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/25/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/24/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/24/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/23/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/22/2024

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Eliem Therapeutics logo
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.
Read More

Today's Range

Now: $2.74
Low: $2.65
High: $2.74

50 Day Range

MA: $2.75
Low: $2.56
High: $2.97

52 Week Range

Now: $2.74
Low: $2.34
High: $4.25

Volume

17,684 shs

Average Volume

5,260 shs

Market Capitalization

$75.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.44

Frequently Asked Questions

What sell-side analysts currently cover shares of Eliem Therapeutics?

The following equities research analysts have issued research reports on Eliem Therapeutics in the last twelve months: HC Wainwright.
View the latest analyst ratings for ELYM.

What is the current price target for Eliem Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Eliem Therapeutics in the last year. Their average twelve-month price target is $6.00, suggesting a possible upside of 119.0%. HC Wainwright has the highest price target set, predicting ELYM will reach $6.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $6.00 for Eliem Therapeutics in the next year.
View the latest price targets for ELYM.

What is the current consensus analyst rating for Eliem Therapeutics?

Eliem Therapeutics currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ELYM, but not buy more shares or sell existing shares.
View the latest ratings for ELYM.

What other companies compete with Eliem Therapeutics?

How do I contact Eliem Therapeutics' investor relations team?

The company's listed phone number is 877-354-3689 and its investor relations email address is [email protected]. The official website for Eliem Therapeutics is www.eliemtx.com. Learn More about contacing Eliem Therapeutics investor relations.